G. H. C. Tan MBBS, FRCS; J. S. M. Wong MBBS; R. Quek MBBS, MRCP; B. K. P. Goh MBBS, FRCS; L. L. Kwok; S. Pan; K. C. Soo MBBS, FRCS; M. C. C. Teo MBBS, FRCS.
Original Article
Role of upfront surgery for recurrent gastrointestinal stromal tumours
Article first published online: 14 JUL 2015
DOI: 10.1111/ans.13220
© 2015 Royal Australasian College of Surgeons
Issue

ANZ Journal of Surgery
Early View (Online Version of Record published before inclusion in an issue)
Additional Information
How to Cite
Tan, G. H. C., Wong, J. S. M., Quek, R., Goh, B. K. P., Kwok, L. L., Pan, S., Soo, K. C. and Teo, M. C. C. (2015), Role of upfront surgery for recurrent gastrointestinal stromal tumours. ANZ Journal of Surgery. doi: 10.1111/ans.13220
Publication History
- Article first published online: 14 JUL 2015
- Manuscript Accepted: 12 MAY 2015
- Abstract
- Article
- References
- Cited By
Keywords:
- GIST;
- recurrence;
- surgery
Abstract
Background
Gastrointestinal stromal tumours (GISTs), despite complete surgical cytoreduction, are associated with recurrence rates of up to 50% at 2 years. At recurrence, tyrosine kinase inhibitor (TKI) therapy is recommended, conferring a survival of up to 55 months. Several studies have shown that patients with TKI-responsive recurrent GIST benefit from surgery. However, no studies have compared upfront surgery versus TKI alone.
Methods
Data were retrospectively collected from patients with recurrent GIST treated at Singapore General Hospital and National Cancer Centre Singapore over a 12-year period. Our primary end points were disease-free and overall survival (OS).
Results
A total of 186 patients underwent curative surgery for GIST between January 2000 and June 2012. Fifty-six (30%) patients experienced recurrence, of which 30 (54%) had resectable recurrent disease. Twenty-four patients underwent upfront surgery for their recurrence while the remaining six patients opted for non-surgical management. The median OS for all patients with recurrent GIST was 5.3 years (95% confidence interval (CI) 3.2–8.4). It was not reached for patients who underwent curative surgery for their recurrence, and was 3.9 years (95% CI 2.4–7.0) for patients who had palliative TKI and conservative management. There were significant differences in OS and disease-specific survival between patients who underwent curative surgery for recurrence compared with those who had not.
Conclusion
Our study shows that upfront surgery is a reasonable treatment strategy for selected patients with recurrent GIST.
